Member Info for Mulder

.

Further you said Aspen paid 2xEBITDA for what was 4 hospitals.

2xEBITDA for Spire is £250M

Spire own FORTY hospitals not 4.
This gives £2.5Bn

This is your own mad calculation.

Do you know how to calculate the book price of a company? Please tell us what the price to book ratio is here and also what the tangible asset value is.

You clearly don't own any shares here then and are shorting.

Never heard of Aspen but it seems NMC acquired 4 hospitals and the rest were fertility clinics.

Applying your 2xEBITDA model for what were in fact 4 hospitals to Spire's 40 gives Spire a value of £2.5Bn or about £6 a share!

That will do...

Meanwhile those long here should take comfort in the fact property, plant and equipment alone is over a £1Bn and twice the current market cap. As is the NAV.

The Week Ahead
Vodafone

It's been a terrible year for Vodafone. Its shares have plunged 40% since the early January peak and currently show little sign of being capable of recovery. Big issue here are worries about competition both in Italy and Spain.

Despite the pessimism, analyst at UBS think the market has got it wrong. "We think Q2 results will show that the broader group remains resilient and that underlying estimates should remain underpinned," writes analyst Polo Tang.

There's revenue growth across most of the business, but UBS reckons Spain will cause a 0.6% drop in Q2 organic service revenue. However, adjust for the handset financing drag in the UK, and revenue could be up 0.5%.

Underlying cash profit is tipped to rise by 1.6% in the first half, and Vodafone is widely expected to repeat guidance for 1-5% organic EBITDA growth for the full-year, although many think it will be more like 2%.

UBS trims its price target to 230p from 250p to reflect "higher Italian spectrum costs, lower EBITDA in the UK and a lower valuation for the VodafoneZiggo JV.

We see the stock as cheap on 11% calendarised equity free cash flow (EFCF) yield and a 9% dividend yield for 2018.

taking place again right now.

Down over 5% on very low volume.
Blatant manipulation by the shorters Connor, Clark and Lunn + Marshall Wace.

Likely to have news about full year for Mediclinic and Spire's future.

Mediclinic will be presenting their full year results next Thursday - the same day Spire trades ex-dividend for the interim.

Yes Marshall Wace have reduced their short position by 60% within a couple of weeks.

Charts pointing to a return to 100-110p

Makes even more sense now.

As of 5th Nov.

& on low volumes (apparently)....

Equivalent JSE price currently 8.45p

Bid here 8.01p

.

No doubt IMO they are in talks with Spire again about a full takeover again - the bidders share price nearly always falls.

Mediclinic down 6% today.

Spire closes up 6%.

Mediclinic full year results next week with update on what they intend to do with their 29.9% stake in Spire......unless news is released before...

Given the sharp drop in Mediclinic's SP today and the opposite happening here another bid from them could be imminent.

Marshall Wace??

Low volume.

Baberton production ahead of expectations.